ALLK - Allakos: Potential For Comeback With Lirentelimab With 2 Indications
Summary
- Results from the phase 2b study, using lirentelimab for the treatment of patients with chronic spontaneous urticaria, are expected in the 2nd half of 2023.
- Xolair naive CSU cohort of 13 patients started with an average UAS7 score of 18.5 points at baseline and at week 22 dropped down to 4.6 points.
- Results from the phase 2b study, using lirentelimab for the treatment of patients with atopic dermatitis, are expected in the 2nd half of 2023.
- Allakos had $212.4 million in cash as of June 30, 2022, but just recently raised $150 million in a public offering. I believe it should have sufficient cash to fund its operations until late 2023.
For further details see:
Allakos: Potential For Comeback With Lirentelimab With 2 Indications